Skip to content

house · Committee report

H. Rept. 118-743

MEDICAID VBPS FOR PATIENTS ACT

2024-11-18

Committees

Associated legislation

Text

Minority Views

[To accompany H.R. 2666] The Committee on Energy and Commerce, to whom was referred the bill (H.R. 2666) to amend title XIX of the Social Security Act to codify value-based purchasing arrangements under the Medicaid program and reforms related to price reporting under such arrangements, and for other purposes, having considered the same, reports favorably thereon with an amendment and recommends that the bill as amended do pass. CONTENTS Purpose and Summary.............................................. 4 Background and Need for Legislation.............................. 4 Committee Action................................................. 4 Committee Votes.................................................. 5 Oversight Findings and Recommendations........................... 7 New Budget Authority, Entitlement Authority, and Tax Expenditures 7 Congressional Budget Office Estimate............................. 7 Federal Mandates Statement....................................... 7 Statement of General Performance Goals and Objectives............ 7 Duplication of Federal Programs.................................. 7 Related Committee and Subcommittee Hearings...................... 7 Committee Cost Estimate.......................................... 8 Earmark, Limited Tax Benefits, and Limited Tariff Benefits....... 8 Advisory Committee Statement..................................... 8 Applicability to Legislative Branch.............................. 8 Section-by-Section Analysis of the Legislation................... 8 Changes in Existing Law Made by the Bill, as Reported............ 9 Minority Views................................................... 68 The amendment is as follows: Strike all after the enacting clause and insert the following: SECTION 1. SHORT TITLE. This Act may be cited as the ``Medicaid VBPs for Patients Act'' or the ``MVP Act''. SEC. 2. CODIFYING VALUE-BASED PURCHASING ARRANGEMENTS UNDER MEDICAID AND REFORMS RELATED TO PRICE REPORTING UNDER SUCH ARRANGEMENTS. (a) Codifying Multiple Best Price Points.-- (1) In general.--Section 1927(c)(1)(C)(ii) of the Social Security Act (42 U.S.C. 1396r-8(c)(1)(C)(ii)) is amended-- (A) in subclause (IV), by striking ``and'' at the end; (B) in subclause (V), by striking the period and inserting ``; and''; and (C) by adding at the end the following new subclause: ``(VI) may include multiple best price points for a single dosage form and strength of a drug of a manufacturer subject to a value-based purchasing arrangement (as defined in subsection (k)(12)), but only if such manufacturer offers such arrangement to all States.''. (2) Rule of construction.--Nothing in the amendments made by this subsection may be construed to prohibit a manufacturer from treating a value-based purchasing arrangement as a bundled sale. (b) Definition of Average Manufacturer Price.-- (1) In general.--Section 1927(k)(1) of the Social Security Act (42 U.S.C. 1396r-8(k)(1)) is amended-- (A) in subparagraph (B)(i)-- (i) in subclause (VII), by striking at the end ``and''; (ii) in subclause (VIII), by striking the period at the end and inserting ``; and''; and (iii) by adding at the end the following new subclause: ``(IX) with respect to such covered outpatient drug that is sold under a value-based purchasing arrangement (as defined in paragraph (12)) during the rebate period, including such drug that is an inhalation, infusion, instilled, implanted, or injectable drug that is not generally dispensed through a retail community pharmacy-- ``(aa) a refund, rebate, reimbursement, or free goods from the manufacturer or third party on behalf of the manufacturer; or ``(bb) the withholding or reduction of a payment to the manufacturer or third party on behalf of the manufacturer; that is triggered by a patient who fails to achieve outcomes or measures defined under the terms of such value- based purchasing arrangement during the period for which such arrangement is effective.''; and (B) by adding at the end the following new subparagraph: ``(D) Special rule for certain value-based purchasing arrangements.--For purposes of subparagraph (A), in determining the average price paid to the manufacturer for a covered outpatient drug that is sold under a value-based purchasing arrangement (as defined in paragraph (12)) that provides that payment for such drug is made in installments over the course of such agreement, such price shall be determined as if the aggregate price per the terms of the agreement was paid in full in the first installment during the rebate period.''. (2) Rulemaking.--Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Human Services shall implement the amendments made by this subsection through rulemaking. (c) Definition of Value-based Purchasing Arrangement.--Section 1927(k) of the Social Security Act (42 U.S.C. 1396r-8(k)) shall be amended by adding at the end the following paragraph: ``(12) Value-based purchasing arrangement.--The term `value- based purchasing arrangement' has the meaning given such term in section 447.502 of title 42, Code of Federal Regulations (or any successor regulation).''. SEC. 3. CALCULATION OF AVERAGE SALES PRICE UNDER MEDICARE. Section 1847A(c)(3) of the Social Security Act (42 U.S.C. 1395w- 3a(c)(3)) is amended-- (1) by striking ``In calculating'' and inserting the following: ``(A) In general.--Subject to subparagraph (B), in calculating''; and (2) by adding at the end the following new subparagraph: ``(B) Certain remuneration under value-based purchasing arrangements excluded.--In calculating the manufacturer's average sales price under this subsection for a drug or biological that is sold under a value-based purchasing arrangement (as defined in section 1927(k)(12)) and with respect to which the manufacturer of such drug or biological has elected to include multiple best price points (as described in section 1927(c)(1)(C)(ii)(VI)) in reporting the best price of such drug under section 1927(b), such price shall not include any amount that is excluded from the calculation of the average manufacturer price of such drug or biological under section 1927(k)(1)(B)(i)(IX).''. SEC. 4. GUIDANCE ON VALUE-BASED PURCHASING ARRANGEMENTS FOR INPATIENT DRUGS UNDER MEDICAID. Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Human Services shall issue guidance to State Medicaid agencies on the option of entering into a value-based purchasing arrangement (as defined in section 1927(k)(12) of the Social Security Act (42 U.S.C. 1396r-8(k)(12))) with manufacturers for drugs or biological products provided as part of, or as incident to and in the same setting as, inpatient hospital services furnished under a State plan under title XIX of the Social Security Act (42 U.S.C. 1396 et seq.), or under a waiver of such plan, where such drugs or biological products are reimbursed directly and not paid for as part of payment for such inpatient hospital services, including guidance on how multiple States may enter into agreements with one another and with manufacturers which permit the transfer of funds between the participating States so that individuals who reside in a State different from the State in which they receive a drug subject to a value-based purchasing arrangement as an inpatient may be treated as if they received such drug in the State in which they reside. SEC. 5. EXCEPTION UNDER THE ANTIKICKBACK STATUTE. (a) In General.--Section 1128B(b)(3) of the Social Security Act (42 U.S.C. 1320a-7b(b)(3)) is amended-- (1) in subparagraph (J), by moving the left margin of such subparagraph 2 ems to the left; (2) in subparagraph (K)-- (A) by moving the left margin of such subparagraph 2 ems to the left; and (B) by striking ``and'' at the end; (3) in subparagraph (L)(iii), by striking the period and inserting ``; and''; and (4) by adding at the end the following new subparagraph: ``(M) any remuneration provided by a manufacturer or third party on behalf of a manufacturer to a State under a value-based purchasing arrangement (as defined in section 1927(k)(12)) under a State plan under title XIX (or waiver of such plan) in the case a patient fails to achieve outcomes or measures defined in such arrangement following the administration of a covered outpatient drug (as defined in section 1927(k)(2)).''. (b) Rulemaking.--Not later than 180 days after the date of the enactment of this Act, the Inspector General of the Department of Health and Human Services shall through rulemaking implement the amendments made by this section. SEC. 6. GAO STUDY AND REPORT ON USE OF VALUE-BASED PURCHASING ARRANGEMENTS. (a) Study.--The Comptroller General of the United States shall conduct a study on the extent to which value-based purchasing arrangements (as defined in section 1927(k)(12) of the Social Security Act (42 U.S.C. 1396r-8(k)(12)) facilitate patient access to covered outpatient drugs, improve patient outcomes, lower overall health system costs, and lower costs for patients in Federal health care programs. In conducting such study, the Comptroller General shall-- (1) study the impact of this Act on-- (A) access to transformative therapies, including rare disease gene therapies, generally; (B) mitigating socioeconomic disparities in accessing covered outpatient drugs sold under value-based purchasing arrangements through its requirement that State Medicaid programs have access to the same value- based purchasing arrangement pricing structure that are available in the commercial market for such drugs; (C) the Medicaid drug rebate program under section 1927 of the Social Security Act (42 U.S.C. 1396r-8), the 340B drug pricing program under section 340B of the Public Health Service Act (42 U.S.C. 256b), and part B of title XVIII of the Social Security Act (42 U.S.C. 1395j et seq.), including compliance with such programs; (D) expenditures under State Medicaid programs; and (E) prices for such drugs under the Medicaid program in States that do not enter into such arrangements; (2) analyze all the types of value-based purchasing arrangement pricing structures, which structures are working well (as measured by price and ease of implementing), and which need improvement; and (3) study the potential long-term savings for States that enter into such arrangements under State Medicaid programs. (b) Report.--Not later than June 30, 2028, the Comptroller General of the United States shall submit to Congress a report containing the results of the study conducted under subsection (a).

Purpose and Summary

The bill amends Medicare and Medicaid policies to support opportunities for States to enter into value-based purchasing arrangements with drug manufacturers to manage the costs of certain drugs in the Medicaid program.

Background and Need for Legislation

The current decade is poised to bring seismic changes to health care, as breakthrough treatments for cell and gene therapies come to market for the first time. Therapies to cure diseases like sickle cell disease and hemophilia, diseases where medicine could only help manage symptoms, could lead to opportunities where patients no longer need regular doctors' appointments and hospitalizations, saving them time and money and supporting a more secure future. The Medicaid program, which disproportionately covers children and people with disabilities who stand to benefit the most from many of these potential treatments, will be integral in covering these therapeutics. However, many of these treatments will likely be high-cost, one-time treatments that will have significant budgetary implications for States in the short run that could disrupt State financing and an ability to cover these treatments, even if the eventual cures will save States money in the long run. As such, value-based purchasing arrangements have emerged as a means for States to help manage these costs by allowing States to pay over multiple installments for a drug and by allowing States to pay for a drug only if the patient meets key clinical endpoints. However, statutory barriers in Medicare and Medicaid limit the ability for States to enter these types of agreements. Thus, H.R. 2666 would make necessary amendments to current law to facilitate these types of agreements.

Committee Action

On April 26, 2023, the Subcommittee on Health held a hearing on H.R. 2666. The title of the hearing was ``Lowering Unaffordable Costs: Legislative Solutions to Increase Transparency and Competition in Health Care.'' The Subcommittee received testimony from: Chiquita Brooks-LaSure, Administrator, U.S. Centers for Medicare and Medicaid Services; Ashley Thompson, Senior Vice President, Public Policy Analysis and Development, American Hospital Association; Kristin Bass, Chief Policy and External Affairs Officer, Pharmaceutical Care Management Association; Brian Connell, Executive Director, Federal Affairs, The Leukemia and Lymphoma Society; Sean Cavanaugh, Chief Policy Officer, Aledade, Inc.; Ilyse Schuman, Senior Vice President, Health Policy, American Benefits Council; and Loren Adler, Fellow and Associate Director, USC-Brookings Initiative for Health Policy, Economic Studies Program, Brookings Institution. On May 17, 2023, the Subcommittee on Health met in open markup session and forwarded H.R. 2666, as amended, to the full Committee by a record vote of 16 yeas and 11 nays. On May 24, 2023, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 2666, as amended, favorably reported to the House by a record vote of 31 yeas and 19 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 2666 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to codify value-based purchasing arrangements under the Medicaid program. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 2666 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 2666: On April 26, 2023, the Subcommittee on Health held a hearing on H.R. 2666. The title of the hearing was ``Lowering Unaffordable Costs: Legislative Solutions to Increase Transparency and Competition in Health Care.'' The Subcommittee received testimony from: Chiquita Brooks-LaSure, Administrator, U.S. Centers for Medicare and Medicaid Services; Ashley Thompson, Senior Vice President, Public Policy Analysis and Development, American Hospital Association; Kristin Bass, Chief Policy and External Affairs Officer, Pharmaceutical Care Management Association; Brian Connell, Executive Director, Federal Affairs, The Leukemia and Lymphoma Society; Sean Cavanaugh, Chief Policy Officer, Aledade, Inc.; Ilyse Schuman, Senior Vice President, Health Policy, American Benefits Council; and Loren Adler, Fellow and Associate Director, USC-Brookings Initiative for Health Policy, Economic Studies Program, Brookings Institution. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 2666 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title Section 1 provides that the Act may be cited as the ``Medicaid VBPs for Patients Act'' or the ``MVP Act''. Section 2. Codifying value-based purchasing arrangements under Medicaid and reforms related to price reporting under such arrangements Section 2 codifies the ability for drug manufacturers to report multiple best prices in Medicaid for a drug, if the manufacturer is engaged in a value-based purchasing arrangement for the drug. This section also amends the calculation of Average Manufacturer Price to account for multiple best prices reported for drugs in value-based purchasing arrangements, and requires rulemaking to implement this provision. The section also defines value-based purchasing arrangements in statute. Section 3. Calculation of average sales price under Medicare Section 3 amends the calculation of Average Sales Price to account for multiple best prices reported for drugs in value- based purchasing arrangements. Section 4. Guidance on value-based purchasing arrangements for inpatient drugs under Medicaid Section 4 requires the Department of Health and Human Services (HHS) to issue guidance clarifying the ability for States and manufacturers to enter into value-based purchasing arrangements for drugs dispensed in inpatient settings. Section 5. Exception under the Antikickback Statute Section 5 creates an exception in the Antikickback Statute for payments made by manufacturers to States when the manufacturer is in a value-based purchasing agreement with a State and when a patient in such an arrangement fails to achieve outcomes or measures specified by the arrangement. The section also requires rulemaking to implement this section. Section 6. GAO study and report on use of value-based purchasing arrangements Section 6 requires the Comptroller General to study the extent to which value-based purchasing agreements facilitate access to respective drugs. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): SOCIAL SECURITY ACT * * * * * * * TITLE XI--GENERAL PROVISIONS, PEER REVIEW, AND ADMINISTRATIVE SIMPLIFICATION * * * * * * * Part A--General Provisions * * * * * * * criminal penalties for acts involving federal health care programs Sec. 1128B. (a) Whoever-- (1) knowingly and willfully makes or causes to be made any false statement or representation of a material fact in any application for any benefit or payment under a Federal health care program (as defined in subsection (f)), (2) at any time knowingly and willfully makes or causes to be made any false statement or representation of a material fact for use in determining rights to such benefit or payment, (3) having knowledge of the occurrence of any event affecting (A) his initial or continued right to any such benefit or payment, or (B) the initial or continued right to any such benefit or payment of any other individual in whose behalf he has applied for or is receiving such benefit or payment, conceals or fails to disclose such event with an intent fraudulently to secure such benefit or payment either in a greater amount or quantity than is due or when no such benefit or payment is authorized, (4) having made application to receive any such benefit or payment for the use and benefit of another and having received it, knowingly and willfully converts such benefit or payment or any part thereof to a use other than for the use and benefit of such other person, (5) presents or causes to be presented a claim for a physician's service for which payment may be made under a Federal health care program and knows that the individual who furnished the service was not licensed as a physician, or (6) for a fee knowingly and willfully counsels or assists an individual to dispose of assets (including by any transfer in trust) in order for the individual to become eligible for medical assistance under a State plan under title XIX, if disposing of the assets results in the imposition of a period of ineligibility for such assistance under section 1917(c), shall (i) in the case of such a statement, representation, concealment, failure, conversion, or provision of counsel or assistance by any other person in connection with the furnishing (by that person) of items or services for which payment is or may be made under the program, be guilty of a felony and upon conviction thereof fined not more than $100,000 or imprisoned for not more than 10 years or both, or (ii) in the case of such a statement, representation, concealment, failure, conversion, or provision of counsel or assistance by any other person, be guilty of a misdemeanor and upon conviction thereof fined not more than $20,000 or imprisoned for not more than one year, or both. In addition, in any case where an individual who is otherwise eligible for assistance under a Federal health care program is convicted of an offense under the preceding provisions of this subsection, the administrator of such program may at its option (notwithstanding any other provision of such program) limit, restrict, or suspend the eligibility of that individual for such period (not exceeding one year) as it deems appropriate; but the imposition of a limitation, restriction, or suspension with respect to the eligibility of any individual under this sentence shall not affect the eligibility of any other person for assistance under the plan, regardless of the relationship between that individual and such other person. (b)(1) Whoever knowingly and willfully solicits or receives any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind-- (A) in return for referring an individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part under a Federal health care program, or (B) in return for purchasing, leasing, ordering, or arranging for or recommending purchasing, leasing, or ordering any good, facility, service, or item for which payment may be made in whole or in part under a Federal health care program, shall be guilty of a felony and upon conviction thereof, shall be fined not more than $100,000 or imprisoned for not more than 10 years, or both. (2) Whoever knowingly and willfully offers or pays any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind to any person to induce such person-- (A) to refer an individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part under a Federal health care program, or (B) to purchase, lease, order, or arrange for or recommend purchasing, leasing, or ordering any good, facility, service, or item for which payment may be made in whole or in part under a Federal health care program, shall be guilty of a felony and upon conviction thereof, shall be fined not more than $100,000 or imprisoned for not more than 10 years, or both. (3) Paragraphs (1) and (2) shall not apply to-- (A) a discount or other reduction in price obtained by a provider of services or other entity under a Federal health care program if the reduction in price is properly disclosed and appropriately reflected in the costs claimed or charges made by the provider or entity under a Federal health care program; (B) any amount paid by an employer to an employee (who has a bona fide employment relationship with such employer) for employment in the provision of covered items or services; (C) any amount paid by a vendor of goods or services to a person authorized to act as a purchasing agent for a group of individuals or entities who are furnishing services reimbursed under a Federal health care program if-- (i) the person has a written contract, with each such individual or entity, which specifies the amount to be paid the person, which amount may be a fixed amount or a fixed percentage of the value of the purchases made by each such individual or entity under the contract, and (ii) in the case of an entity that is a provider of services (as defined in section 1861(u)), the person discloses (in such form and manner as the Secretary requires) to the entity and, upon request, to the Secretary the amount received from each such vendor with respect to purchases made by or on behalf of the entity; (D) a waiver of any coinsurance under part B of title XVIII by a Federally qualified health care center with respect to an individual who qualifies for subsidized services under a provision of the Public Health Service Act; (E) any payment practice specified by the Secretary in regulations promulgated pursuant to section 14(a) of the Medicare and Medicaid Patient and Program Protection Act of 1987 or in regulations under section 1860D-3(e)(6); (F) any remuneration between an organization and an individual or entity providing items or services, or a combination thereof, pursuant to a written agreement between the organization and the individual or entity if the organization is an eligible organization under section 1876 or if the written agreement, through a risk-sharing arrangement, places the individual or entity at substantial financial risk for the cost or utilization of the items or services, or a combination thereof, which the individual or entity is obligated to provide; (G) the waiver or reduction by pharmacies (including pharmacies of the Indian Health Service, Indian tribes, tribal organizations, and urban Indian organizations) of any cost-sharing imposed under part D of title XVIII, if the conditions described in clauses (i) through (iii) of section 1128A(i)(6)(A) are met with respect to the waiver or reduction (except that, in the case of such a waiver or reduction on behalf of a subsidy eligible individual (as defined in section 1860D-14(a)(3)), section 1128A(i)(6)(A) shall be applied without regard to clauses (ii) and (iii) of that section); (H) any remuneration between a federally qualified health center (or an entity controlled by such a health center) and an MA organization pursuant to a written agreement described in section 1853(a)(4); (I) any remuneration between a health center entity described under clause (i) or (ii) of section 1905(l)(2)(B) and any individual or entity providing goods, items, services, donations, loans, or a combination thereof, to such health center entity pursuant to a contract, lease, grant, loan, or other agreement, if such agreement contributes to the ability of the health center entity to maintain or increase the availability, or enhance the quality, of services provided to a medically underserved population served by the health center entity; (J) a discount in the price of an applicable drug (as defined in paragraph (2) of section 1860D-14A(g)) of a manufacturer that is furnished to an applicable beneficiary (as defined in paragraph (1) of such section) under the Medicare coverage gap discount program under section 1860D-14A; (K) an incentive payment made to a Medicare fee-for- service beneficiary by an ACO under an ACO Beneficiary Incentive Program established under subsection (m) of section 1899, if the payment is made in accordance with the requirements of such subsection and meets such other conditions as the Secretary may establish; [and] (L) a bona fide mental health or behavioral health improvement or maintenance program, if-- (i) such program-- (I) consists of counseling, mental health services, a suicide prevention program, or a substance use disorder prevention and treatment program; (II) is made available to a physician or other clinician for the primary purpose of preventing suicide, improving mental health and resiliency, or providing training in appropriate strategies to promote the mental health and resiliency of such physician or other clinician; (III) is set out in a written policy, approved in advance of the operation of the program by the governing body of the entity providing such program (and which shall be updated accordingly in advance to substantial changes to the operation of such program), that includes-- (aa) a description of the content and duration of the program; (bb) a description of the evidence-based support for the design of the program; (cc) the estimated cost of the program; (dd) the personnel (including the qualifications of such personnel) implementing the program; and (ee) the method by which such entity will evaluate the use and success of the program; (IV) is offered by an entity described in clause (ii) with a formal medical staff to all physicians and other clinicians who practice in the geographic area served by such entity, including physicians who hold bona fide appointments to the medical staff of such entity or otherwise have clinical privileges at such entity; (V) is offered to all such physicians

Minority Views

H.R. 2666, the Medicaid VBPs for Patients Act, would not expand access or increase affordability of drugs or gene therapies in Medicaid. Instead, it would create a loophole in federal law that would increase drug costs to Medicaid, further straining state budgets and making it harder for states to care for their most vulnerable populations. Federal law generally requires state Medicaid programs to cover all Food and Drug Administration (FDA)-approved drugs and biologics of manufacturers that have a signed rebate agreement in place. In exchange for this coverage requirement, drug manufacturers are required to pay statutory rebates that are shared between the states and the federal government.\1\ These statutory rebates are a large source of revenue that help states offset the costs of their Medicaid programs.\2\ --------------------------------------------------------------------------- \1\Medicaid and CHIP Payment and Access Commission (MACPAC), Strengthening Evidence Under Medicaid Drug Coverage (March 2023). \2\Id. --------------------------------------------------------------------------- The Medicaid drug rebate program is highly effective at reducing drug costs.\3\ Medicaid consistently has among the lowest net drug costs of all federal health programs.\4\ A drug's rebate is made up of a base rebate, which is the greater of either 23.1 percent of the average manufacturer price (AMP) for a brand drug, or the best price at which the drug is available on the private market. Additionally, if the quarterly AMP of the drug has increased over the base AMP of the drug at a rate that exceeds inflation, manufacturers must pay an inflationary rebate. Taken together, the Medicaid best price and inflationary rebates are a substantial source of rebates in Medicaid. --------------------------------------------------------------------------- \3\Georgetown University Center for Children and Families, How to Strengthen the Medicaid Drug Rebate Program to Address Rising Medicaid Prescription Drug Costs (Jan. 2019). \4\U.S. Government Accountability Office, Comparison of DOD, Medicaid, and Medicare Part D Retail Reimbursement Prices (June 2014). --------------------------------------------------------------------------- H.R. 2666 would create multiple loopholes in federal law that would undermine both the Medicaid best price policy and the inflationary rebates, resulting in decreased rebates and increased drug costs to states and the federal government. First, the bill would codify a regulation that allows drug manufacturers to report multiple best prices for drugs in value-based payment (VBP) arrangements. State Medicaid programs would only be able to receive these discounts if they entered into the same VBP that generated the best price. In other words, if a drug's non-VBP best price results in a 25 percent discount and the VBP best price results in a 50 percent discount, a state would need to enter into that VBP arrangement in order to receive the 50 percent discount. Unfortunately, most, if not all states lack the financial resources and administrative capabilities to participate in VBPs, which means that under this structure, states will not benefit from these VBP discounts. Accordingly, drug manufacturers will be able to structure their most generous discount agreements as VBPs with terms that make them inaccessible to state Medicaid programs and, therefore, result in reduced rebates and increased costs to Medicaid. This will put further strain on state budgets. In addition to the best price loophole, H.R. 2666 would undermine Medicaid inflationary rebates by excluding VBP prices from the calculation of AMP. A manufacturer launching a new product would be able to structure some or all of its sales as VBPs, which would artificially increase the AMP. By artificially increasing the AMP, manufacturers will be able to delay the onset of inflationary rebates. This will deprive states and the federal government of yet another important source of rebates and further strain state budgets. Multiple commenters echoed these concerns and others in their comments on the regulation that H.R. 2666 would codify. The National Association of Medicaid Directors (NAMD), a bipartisan association that represents all the state Medicaid directors, said ``the rule's proposals would greatly favor manufacturers over states in terms of financial benefit, have significant impacts on the Medicaid pharmacy benefit, undermine best price protections that ensure the sustainability of Medicaid pharmacy budgets, and place substantial strain on state administrative resources.''\5\ Similarly, the Medicaid and CHIP Payment and Access Commission (MACPAC) wrote ``[t]he proposed definition of VBP and changes to Medicaid best price could lead to decreased rebates, and thus increased Medicaid spending, while also increasing administrative burden on states. Specifically, the Commission is concerned that while these changes could incentivize the use of VBP in the commercial market, they would also negatively affect the Medicaid program and do little to address concerns about the impact of high-cost specialty drugs on Medicaid program spending.''\6\ --------------------------------------------------------------------------- \5\National Association of Medicaid Directors, Comments on Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements'' [CMS-2482-P] (July 20, 2020). \6\MACPAC, Comments on Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (July 20, 2020). --------------------------------------------------------------------------- H.R. 2666 would codify harmful changes to the Medicaid drug rebate program that would increase costs to states and the federal government. It would create multiple loopholes, increase administrative burdens on states, and fail to increase access or reduce the cost of drugs to state Medicaid programs. Frank Pallone, Jr., Ranking Member. [all]

Source: https://api.congress.gov/v3/committee-report/118/hrpt/743